RPL19, which is a tumor-specific antigen of lung adenocarcinoma (Kuroda et al., 2010), can also be used as a prognostic biomarker for prostate cancer (Bee et al., 2006), colorectal cancer (Huang et al., 2008), and diffuse large B-cell lymphoma (Yan et al., 2019). Here, RPL19 is linked to diffuse large B-cell lymphoma.